MMP-2 SiRNA Induced Fas/CD95-mediated Extrinsic II Apoptotic Pathway in the A549 Lung Adenocarcinoma Cell Line

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2007 Jun 30

PMID 17599056

Citations 27

Authors

C Chetty

P Bhoopathi

S S Lakka

J S Rao

Affiliations

Soon will be listed here.

Abstract

We have previously reported that the downregulation of MMP-2 by adenovirus-mediated delivery of MMP-2 siRNA (Ad-MMP-2) reduced spheroid invasion and angiogenesis in vitro, and, metastasis and tumor growth in vivo. In this study, we investigated the mechanism of Ad-MMP-2-mediated growth inhibition in vitro and in vivo. Ad-MMP-2 infection led to the induction of apoptosis as determined by TUNEL assay, Annexin-V staining and PARP-1 cleavage in a dose-dependent manner in A549 cells. Ad-MMP-2 decreased the content of the antiapoptotic members of the Bcl-2 family proteins (Bcl-2 and Bcl-xL) and increased the content of the pro-apoptotic members of the Bcl-2 family (Bax and Bcl-xS) as determined by immunoblotting analysis. Furthermore, Ad-MMP-2-mediated apoptosis was accompanied by increase in truncated Bid, release of cytochrome c and the activation of caspase-8, -9 and -3. Immunoblot analysis showed that Ad-MMP-2 infection caused upregulation of Fas/Fas-L and FADD, and Anti-Fas-L antibody reversed Ad-MMP-2-induced apoptosis. Tissue inhibitor of metalloproteinases (TIMP)-3, an endogenous inhibitor of MMP-2, which cleaves Fas-L and activates the Fas/Fas-L inducing apoptotic pathway, was increased in Ad-MMP-2-treated cells. Adenovirus-mediated expression of MMP-2 siRNA in human lung xenografts in vivo resulted in increased immunostaining of Fas, Fas-L, cleaved Bid and TIMP-3. This is the first report, to our knowledge, showing that MMP-2 inhibition upregulates TIMP-3 levels, which in turn, promotes apoptosis in lung cancer.

Citing Articles

Amelioration of Pulmonary Fibrosis by Matrix Metalloproteinase-2 Overexpression.

Inoue R, Yasuma T, DAlessandro V, Toda M, Ito T, Tomaru A Int J Mol Sci. 2023; 24(7).

PMID: 37047672 PMC: 10095307. DOI: 10.3390/ijms24076695.

Vicenin-2: a potential radiosensitizer of non-small cell lung cancer cells.

Baruah T, Sharan R, Kma L Mol Biol Rep. 2018; 45(5):1219-1225.

PMID: 30099686 DOI: 10.1007/s11033-018-4275-8.

HIV infection model of chronic obstructive pulmonary disease in mice.

Geraghty P, Hadas E, Kim B, Dabo A, Volsky D, Foronjy R Am J Physiol Lung Cell Mol Physiol. 2017; 312(4):L500-L509.

PMID: 28104604 PMC: 5407095. DOI: 10.1152/ajplung.00431.2016.

MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC.

Joshi P, Jeon Y, Lagana A, Middleton J, Secchiero P, Garofalo M Proc Natl Acad Sci U S A. 2015; 112(28):8650-5.

PMID: 26124099 PMC: 4507199. DOI: 10.1073/pnas.1500886112.

MMI-166, a selective matrix metalloproteinase inhibitor, promotes apoptosis in human pancreatic cancer.

Gao C, Gong B, Wu J, Cheng P, Xu H, Song D Med Oncol. 2014; 32(1):418.

PMID: 25471789 DOI: 10.1007/s12032-014-0418-5.

References

Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao J, Lakka S . Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther. 2006; 5(9):2289-99. DOI: 10.1158/1535-7163.MCT-06-0169. View

Haro H, Crawford H, Fingleton B, Shinomiya K, Spengler D, Matrisian L . Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest. 2000; 105(2):143-50. PMC: 377426. DOI: 10.1172/JCI7091. View

Brew K, Dinakarpandian D, Nagase H . Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000; 1477(1-2):267-83. DOI: 10.1016/s0167-4838(99)00279-4. View

Kang S, Choi H, Kim S, Jong H, Kim N, Kim S . Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation of the 5'-CpG island in human gastric cancer cell lines. Int J Cancer. 2000; 86(5):632-5. DOI: 10.1002/(sici)1097-0215(20000601)86:5<632::aid-ijc5>3.0.co;2-5. View

Hengartner M . The biochemistry of apoptosis. Nature. 2000; 407(6805):770-6. DOI: 10.1038/35037710. View

Brand K, Baker A, Perez-Canto A, Possling A, Sacharjat M, Geheeb M . Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res. 2000; 60(20):5723-30. View

Bond M, Murphy G, Bennett M, Amour A, Knauper V, Newby A . Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity. J Biol Chem. 2000; 275(52):41358-63. DOI: 10.1074/jbc.M007929200. View

Mitsiades N, Poulaki V, Mitsiades C, Anderson K . Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug. Expert Opin Investig Drugs. 2002; 10(6):1075-84. DOI: 10.1517/13543784.10.6.1075. View

Bond M, Murphy G, Bennett M, Newby A, Baker A . Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem. 2002; 277(16):13787-95. DOI: 10.1074/jbc.M111507200. View

10.

Ahonen M, Ala-Aho R, Baker A, George S, Grenman R, Saarialho-Kere U . Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther. 2002; 5(6):705-15. DOI: 10.1006/mthe.2002.0606. View

11.

Spurbeck W, Ng C, Strom T, Vanin E, Davidoff A . Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood. 2002; 100(9):3361-8. DOI: 10.1182/blood.V100.9.3361. View

12.

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

13.

Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez J . Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem. 2002; 278(10):8516-25. DOI: 10.1074/jbc.M210432200. View

14.

Nyormoi O, Mills L, Bar-Eli M . An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells. Cell Death Differ. 2003; 10(5):558-69. DOI: 10.1038/sj.cdd.4401209. View

15.

Strand S, Vollmer P, van den Abeelen L, Gottfried D, Alla V, Heid H . Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene. 2004; 23(20):3732-6. DOI: 10.1038/sj.onc.1207387. View

16.

Birkedal-Hansen H, Moore W, Bodden M, Windsor L, DeCarlo A, Engler J . Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993; 4(2):197-250. DOI: 10.1177/10454411930040020401. View

17.

Cawston T . Proteinases and inhibitors. Br Med Bull. 1995; 51(2):385-401. DOI: 10.1093/oxfordjournals.bmb.a072968. View

18.

Brown P, Giavazzi R . Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol. 1995; 6(10):967-74. DOI: 10.1093/oxfordjournals.annonc.a059091. View

19.

Bao L, Smith R, Iwata K, Olsen B, Zetter B, Apte S . A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth. Biochem Cell Biol. 1996; 74(6):853-62. DOI: 10.1139/o96-090. View

20.

Gomez D, Alonso D, Yoshiji H, Thorgeirsson U . Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997; 74(2):111-22. View